Regen Biopharma Inc (RGBAD)

[RAND]

On April 19, 2021 Regen Biopharma, Inc. (the “Company”) executed an engagement letter with BF Borgers CPA PC ( “Borgers”), the Company’s independent registered public accounting firm, the purpose of which was to retain Borgers to perform an audit of the Company’s balance sheet as of September 30, 2019, the related statement of operations, stockholders' equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the "Financial Statements") for inclusion in a Form 10-K for the year ended September 30, 2019 to be filed with the United States Securities and Exchange Commission (“2019 10-K”) .

The commencement of this audit of the Company’s Financial Statements is the first step in curing the Company’s delinquency with regard to periodic reports required to be filed with the United States Securities and Exchange Commission.